US Patent

US10828297 — Compositions and methods for treating centrally mediated nausea and vomiting

Method of Use · Assigned to Helsinn Healthcare SA · Expires 2030-12-17 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.

USPTO Abstract

Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2301 — fosnetupitant-chloride-hydrochloride
U-2301 — fosnetupitant-chloride-hydrochloride
U-2293 — Akynzeo

Patent Metadata

Patent number
US10828297
Jurisdiction
US
Classification
Method of Use
Expires
2030-12-17
Drug substance claim
No
Drug product claim
No
Assignee
Helsinn Healthcare SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.